Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

Autor: Debayan Mukherjee, Erminia Romano, Richard Walshaw, Leo A. H. Zeef, Antonia Banyard, Stephen J. Kitcatt, Eleanor J. Cheadle, Karoliina Tuomela, Swati Pendharkar, Aws Al-Deka, Beatrice Salerno, Sophie Raby, Ian G. Mills, Jamie Honeychurch, Tim M. Illidge

Publikováno v: OncoImmunology, Vol 12, Iss 1 (2023)

ABSTRACTDespite breakthroughs in immune checkpoint inhibitors (ICI), the majority of tumors, including those poorly infiltrated by CD8+ T cells or heavily infiltrated by immunosuppressive immune effector cells, are unlikely to result in clinically me

Externí odkaz: https://doaj.org/article/9f867c6013ac405080b84ec982759eae

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma

Autor: Tim M. Illidge, Elizabeth H. Phillips, Nicholas Counsell, Ruth Pettengell, Peter W.M. Johnson, Dominic J. Culligan, Bilyana Popova, Laura Clifton-Hadley, Andrew McMillan, Peter Hoskin, Sally F. Barrington, John Radford

Publikováno v: Blood Advances, Vol 4, Iss 1, Pp 203-206 (2020)

Externí odkaz: https://doaj.org/article/22a017ba18324963a873caf2b7ad3390

Supplemental Figures 1 - 7 from Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

Autor: Tim M. Illidge, Jamie Honeychurch, Robert W. Wilkinson, Hazel Jones, Ross Stewart, Michelle Morrow, Edmund Poon, Ian J. Stratford, Eleanor J. Cheadle, Sherrie Jones, Conor McKenna, Grazyna Lipowska-Bhalla, Amy L. Adlard, Simon J. Dovedi

Supplemental figure 1: Gating strategy for determining tumor cell PD-L1 expression. Supplemental figure 2: Impact of low-dose fractionated RT on PD-L1 expression by CD11b+GR1Hi cells. Supplemental figure 3: Dual blockade of PD-1 and PD-L1 does not fu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18798dd2b1411cce7bf46bf133395698
https://doi.org/10.1158/0008-5472.22403754.v1

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

Autor: Illidge TM; Tim M. Illidge, Sam Mayes, John A. Radford, W. David J. Ryder, Manchester Academic Health Science Centre, University of Manchester; Jill Tipping, Maureen Zivanovic, Christie Hospital NHS Foundation Trust, Manchester; Ruth Pettengell, St. George's, University of London, London; Andrew T. Bates, Southampton University Hospitals NHS Foundation Trust, Southampton; Mike Bayne, Poole Hospital NHS Foundation Trust, Dorset, United Kingdom; Steven Le Gouill, Centre Hospitalier Universitaire Nantes; Françoise Kraeber-Bodere, Caroline Bodet-Milin, University Hospital-ICO-CRCNA INSERM U892, Nantes; Emmanuel Malek, Damien Huglo, Hospitalier Universitaire Lille; Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Fabrice Jardin, Centre Henri Becquerel, Rouen; Manuel Bardies, Centre de Recherche en Cancérologie de Toulouse, Faculté de Médecine de Toulouse-Rangueil, Toulouse, France., Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, Ryder WD, Le Gouill S, Jardin F, Tipping J, Zivanovic M, Kraeber-Bodere F, Bardies M, Bodet-Milin C, Malek E, Huglo D, Morschhauser F

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Jan 20; Vol. 32 (3), pp. 212-8. Date of Electronic Publication: 2013 Dec 02.